Medications That Can Cause Tardive Dyskinesia: Guide

Tardive dyskinesia (TD) is a movement disorder that can appear after months or years of taking certain medicines.

It causes involuntary, repetitive movements—often of the face, lips, tongue, or limbs—that can affect confidence, social life, and daily functioning.

This guide explains which medications can cause TD, who is at higher risk, what symptoms to watch for, and evidence-based treatment options. It’s educational only and not a substitute for medical advice—always work with your prescriber before changing any medication.

What is tardive dyskinesia?

TD is a long-term side effect linked mainly to medicines that block dopamine receptors. Common signs include lip smacking, chewing motions, tongue protrusion, grimacing, blinking, rocking, or choreiform movements of the arms and legs. You can learn more about TD basics from MedlinePlus and a detailed overview in StatPearls.

TD risk rises with cumulative exposure to dopamine receptor–blocking agents (DRBAs), especially antipsychotics and some anti-nausea drugs. Other contributors include older age, female sex, diabetes, mood disorders, and a history of substance use.

While newer “atypical” antipsychotics generally have a lower TD risk than older ones, no DRBA is risk-free. Estimates vary, but long-term exposure can lead to TD in a notable minority of patients; early recognition and action can reduce its impact.

5 medications that can cause tardive dyskinesia

Many medicines can contribute to TD, particularly dopamine-blocking antipsychotics and certain gastrointestinal agents. Here are five well-known examples (not a complete list):

1. Haloperidol (Haldol) — a first-generation antipsychotic used for schizophrenia and acute agitation. It carries a well-established TD risk; see safety information on MedlinePlus.
2. Fluphenazine — another first-generation antipsychotic with significant TD risk, especially at higher doses or long-term use. Details: MedlinePlus.
3. Risperidone (Risperdal) — a second-generation antipsychotic. Although TD risk is generally lower than with older agents, it still occurs. Medication guide: MedlinePlus.
4. Olanzapine (Zyprexa) — another second-generation antipsychotic with documented TD cases, particularly with prolonged exposure. More info: MedlinePlus.
5. Metoclopramide (Reglan) — an anti-nausea/GERD medication with a boxed warning for TD risk; long-term use is generally discouraged. See FDA information: FDA safety page.

Other dopamine-blocking agents—such as prochlorperazine or long-acting injectable antipsychotics—can also cause TD. If you’re unsure about your personal risk, ask your clinician to review your medication list (including PRN and over-the-counter drugs).

Who is at higher risk?

• Longer duration and higher doses of antipsychotics or other DRBAs
• Older age, especially over 55
• Female sex
• Diabetes, prediabetes, or metabolic syndrome
• Mood disorders (e.g., depression) and substance use history
• Past extrapyramidal symptoms (e.g., Parkinsonism, akathisia) when starting antipsychotics

How is TD diagnosed and monitored?

TD is a clinical diagnosis based on a patient’s history of DRBA exposure and characteristic movements. Clinicians often use the Abnormal Involuntary Movement Scale (AIMS) to screen and track severity over time; you can see a copy of the tool here.

People on DRBAs should be screened regularly (for example, at baseline, then every 3–6 months). Video or mirror self-checks between visits can help you notice new or worsening movements earlier and report them promptly.

Treatment options that work

1) Talk with your prescriber before making any changes

Do not stop medications on your own. For many, antipsychotics are life-saving. That said, if TD appears, your clinician may consider dose reduction, slower titration, or carefully discontinuing the offending drug when clinically feasible. The risk of relapse must be balanced against TD control.

2) Consider switching strategies

When appropriate, switching to an antipsychotic with a lower TD risk profile (for example, clozapine) may be considered. Decisions depend on diagnosis, past response, and side-effect tolerability. Learn more about clozapine’s uses and safety on MedlinePlus.

3) VMAT2 inhibitors: first-line pharmacologic treatments

Valbenazine and deutetrabenazine are FDA-approved to treat TD. These medicines reduce excessive dopamine release by inhibiting the vesicular monoamine transporter 2 (VMAT2), which can decrease involuntary movements.

• Valbenazine (Ingrezza) — once-daily dosing; common side effects include sleepiness and dry mouth. Details: MedlinePlus.
• Deutetrabenazine (Austedo) — typically twice-daily dosing; monitor for depression and somnolence. More info: MedlinePlus.

Clinical guidelines support VMAT2 inhibitors as effective options for TD; see the practice guideline summary via PubMed. Response often appears within weeks, and benefits can persist with continued therapy.

4) Other therapies sometimes used

• Botulinum toxin injections for focal, function-limiting movements (e.g., jaw, eyelids).
• Physical, occupational, and speech therapy to improve function, posture, and swallowing or speech issues.
• Address contributors such as uncontrolled diabetes, sleep problems, caffeine excess, or other medicines that may worsen movements.
• Be cautious with anticholinergics (e.g., benztropine), which can sometimes worsen TD even if they help other movement side effects.

5) Practical self-management tips

• Keep a symptom diary or short phone videos to document changes between visits.
• Ask about AIMS screening frequency and your personal risk factors.
• Maintain steady sleep, hydration, and nutrition; limit stimulants if they worsen movements.
• Seek support from advocacy groups like NAMI for education and resources.

When to seek urgent care

• New or rapidly worsening movements that impair breathing, swallowing, or walking
• Severe neck or jaw spasms, high fever, confusion, or muscle rigidity
• Thoughts of self-harm or harm to others

These may indicate conditions other than TD or complications that need immediate professional attention.

Key takeaways

• TD is often linked to dopamine-blocking medicines used for psychiatric and gastrointestinal conditions.
• Five examples: haloperidol, fluphenazine, risperidone, olanzapine, and metoclopramide.
• Don’t stop medicines suddenly. Talk with your prescriber about dose adjustments, switching strategies, and VMAT2 inhibitors.
• Early detection matters. Regular AIMS screening and self-monitoring can limit disability and improve outcomes.

With the right plan—careful medication management, evidence-based treatments, and ongoing monitoring—most people can reduce TD symptoms and protect their quality of life.